Conservation biologist Brian Gratwicke searches with his team for frogs in Altos de Campana National Park in Panama. Nate ...

The study of GanLum (KLU156) – a combination of novel drug ganaplacide with established antimalarial lumefantrine – showed ...

Novartis phase III trial for next-generation malaria treatment KLU156 meets primary endpoint, with potential to combat antimalarial resistance: Basel Friday, November 14, 2025, 09 ...

NVS' GanLum meets its phase III goal, showing strong efficacy against drug-resistant malaria and proving non-inferiority to the current standard of care.

In 2022, the WHO hailed Novartis’ GanLum as the most promising non-artemisinin-based combination. The Swiss drugmaker ...

Promising results from a new malaria drug offer hope against emerging drug resistance in Africa. In a clinical trial, ...

In what experts are calling a breakthrough in the global fight against malaria, a new next-generation drug candidate — GanLum ...

Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...

A promising new malaria drug shows incredible promise in fighting resistance and could save thousands of lives.

Novartis plans to seek quick regulatory approvals from health authorities for the drug, known as GanLum, which would be the ...

Explore Laveran's groundbreaking discovery of the malaria parasite and its lasting impact on infectious disease research and ...

An experimental drug was effective against malaria in a new study, potentially offering a much-needed buffer against the ...